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Summary Low pH and hypoxia are a common feature of many solid tumours. This study examined the effect
of these two conditions on the cytotoxic properties of the bifunctional agent RB 6145, the prodrug of RSU
1069. The effect of acidic pH on RB 6145 toxicity was examined in six human tumour cell lines under hypoxic
conditions and was found to have little effect in HT 29, A549, U373 and HT 144 cells. Treatment was for I h
at 37'C, pH 6.4 or 7.4. Significant potentiation of RB 6145 toxicity was observed in SiHa cells (enhancement
ratio; ERpH- 1.6) and in Ul cells (ERpH' 1.4). In these two cell lines the potentiation of RB 6145 toxicity
arising from hypoxia was large, with ERHyp- 11 and 15 in SiHa and U1 cells respectively. SiHa cells, which
show a pH effect and HT 29 cells, which do not, were chosen for further comparative studies of drug uptake
and regulation of intracellular pH. High-performance liquid chromatography (HPLC) determinations of the
uptake of RB 6145 and its dervatives showed that in SiHa cells, intracellular to extracellular drug concentra-
tion ratio (CiICe) at 1 h was - 40% higher at pH 6.4 than at pH 7.4, whereas in HT 29 cells CjCe was -
25% lower. Under conditions of acidic extracellular pH, regulation of pH was somewhat less effective in SiHa
cells, where pHi dropped to within 0.2 pH units of the extracellular pH over a 2.5 h treatment at pH 6.4. It
seems likely that increased drug uptake was at least part of the basis for the observed potentiation of RB 6145
toxicity in SiHa cells. A model which would better explain the results for both cell lines might also include the
possibility that low pH per se potentiates cytotoxic damage to a modest extent and that it is offset or
augmented by altered uptake in HT 29 and SiHa cells respectively.
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Regions of hypoxia (Thomlinson and Gray, 1955; Tannock,
1968) and of low pH (Wike-Hooley et al., 1984; Vaupel et
al., 1991) are a common feature of many solid tumours.
Since hypoxic cells are resistant to killing by radiation and by
some chemotherapeutic drugs (Coleman, 1988), much effort
has been directed at finding ways to specifically target such
cells in tumours. The use of hypoxic cell radiosensitisers such
as the 2-nitroimidazole, misonidazole, has provided some
therapeutic gain, though neurotoxicity limited its dose and
thus its effectiveness. (Dische, 1985; Overgaard et al., 1989).
RSU 1069 [x-(1-aziridinomethyl)-2-nitro-lH-imidazole-1-etha-
nol] was one of the newer generation nitroimidazoles
developed by Adams et al. (1984a,b), and one which
exhibited two functions: radiosensitisation due to the electron
affinic properties of the molecule and alkylation by the
aziridine moiety. It was very efficient both as a radiosensitiser
and as a chemosensitiser, but also produced severe gast-
rointestinal toxicity (Horwich et al., 1986). RB 6145 [a-([(2-
bromoethyl)-aminoJmethyl)-2-nitro-JH-imidazole-1-ethanol
hydrobromide] was developed as an analogue (see Figure 1)
and prodrug of RSU 1069 (Jenkins et al., 1990). It retained
most of the radiosensitisation and bioreductive cytotoxicity
of RSU 1069 but had much lower toxicity (Cole et al., 1990,
1991, 1992; Bremner, 1993), and is currently awaiting clinical
evaluation.
The pharmacokinetics of RB 6145 and its metabolites have
been carefully examined in mice (Binger and Workman,
1991). The major metabolites were shown to be RSU 1069
(the pharmacologically active aziridine ring metabolite) and
an oxazolidinone metabolite, with much lower levels of at
least two other analogues, RSU 1137 and RSU 1111 (see
Figure 1). The i.p. administration of RB 6145 was shown to
give rise to peak plasma and tumour levels of RSU 1069 that
were about half the levels achieved by an equimolar dose of
RSU 1069 itself. Metabolite levels in brain were lower (par-
ticularly the oxazolidinone) when the prodrug RB 6145 was
used, as compared with RSU 1069 and it has been suggested
that this may be part of the reduced in vivo toxicity of RB
6145.
In this report we examine the influence of hypoxia and,
particularly, low pH on the bioreductive cytotoxicity of RB
6145 in human tumour cell lines in vitro, and we attempt to
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Figure 1 Structures of RB 6145 and its derivatives.
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correlate the effect with intracellular levels of the prodrug
and its metabolites.
Materials and methods
Cells
The cell lines SiHa, HT 29, A549, HT 144 and U373MG
were all obtained from American Type Culture Collection
(ATCC). Ul cells were provided by Dr JB Mitchell. The cells
were grown as monolayers at 37°C in a humidified atmo-
sphere of 95% air, and 5% carbon dioxide, using the follow-
ing recommended media: SiHa, HT 144, U373GM, and Ul
in minimum essential medium (MEM; Gibco, Burlington,
Ontario, Canada); HT 29 and A549 in McCoy's 5A (Gibco).
Both types of growth medium were supplemented with 10%
fetal bovine serum (FBS; Gibco), penicillin (80 units ml-'),
streptomycin (80jg ml-') and sodium bicarbonate
(2.2 g 1-). SiHa, A549 and U373GM cells were harvested by
incubating with 0.1% trypsin for 7 min, 5 min and 5 min
respectively. HT 144 and Ul cells were trypsinised with
0.03% trypsin for 2-3 min, and HT 29 cells were trypsinised
with 0.05% trypsin with EDTA (Sigma, St. Louis, MO,
USA) for 3min. All cell lines were neutralised with the
appropriate growth media.
Drugs
The prodrug RB 6145 was obtained from Warner-Lambert.
RSU 1069 was provided by Dr MR Horsman, and was used
for cytotoxicity studies and for product identification. A
small sample of RSU 1137 was obtained from Dr IJ Strat-
ford to facilitate product identification. All drug solutions
were prepared immediately before each experiment, as des-
cribed below. It should be noted that the RB 6145 used in
the present study was a mixture of the R- and S-isomers.
More recently, Warner-Lambert has been producing the R-
isomer for clinical studies because it has lower emetic toxicity
but the same anti-tumour activity as the S-isomer (Adams
and Stratford, 1994).
Cytotoxicity measurement
Cells were spun down at 95g for 7 min and resuspended at
3 x 105 cells ml-' in suspension culture medium (SMEM S14
or S McCoy's 5A) supplemented with 10% FBS and 20 mM
Bis-Tris+ (bis [2-hydroxy-ethyl]imino-tris [hydroxymethyl]
methane) for control of pH. Two suspensions were prepared,
one at pH 6.6 (or 6.4), the other at pH 7.4. From these
suspensions, 9ml was placed into each of 12 wide-mouth,
50 ml Erlenmeyer flasks (six at each pH) fitted with a special
stopper that provided gas-in, gas-out and sampling ports.
These flasks were placed in a 37°C rotary shaker bath and
gassed with humidified nitrogen or air (141 min-') in a 37°C
warm room. After 60 min of gassing, RB 6145 was added in
1 ml of pH-adjusted medium at a concentration that would
give the appropriate final concentration. For each pH, one
flask served as a control and received no drug. After a
further 60min of incubation, aliquots were removed from
each flask, spun down and resuspended in fresh medium
twice to remove the drug. Appropriate inocula were then
plated for colony formation in 60 mm petri dishes, using the
appropriate growth medium supplemented with 10% FBS,
penicillin, streptomycin and sodium bicarbonate. In some
experiments, several different pH values were used along with
a single drug concentration.
RB 6145 was prepared fresh before each experiment. An
appropriate amount of RB 6145 was weighed out and dis-
solved in cold (4°C) SMEM S14 or S McCoy's 5A with 10%
FBS, and 20 mM Bis-Tris at the appropriate pH (6.6 or 7.4).
The drug solution was stirred rapidly on ice, protected from
light for 10 min and sterile filtered before being added to the
vessels.
High-performance liquid chromatography (HPLC) studies of
drug uptake andstability
The drug stability experiments followed the same procedure
as the cytotoxicity and drug uptake studies except that con-
version was measured in medium only, without cells present.
An aliquot of 9 ml of SMEM S14 with 10% FBS and 20 mM
Bis-Tris at pH 7.4 was placed in a 125 ml Erlenmeyer flask,
fitted with a special stopper with ports for gas in, gas out and
sampling. After 60 min preincubation with nitrogen gassing
(141 min-) at 37°C, 1 ml of cold 1 mM RB 6145 at pH 6.9
was added to the flask. After 30s the first 1 ml aliquot
(t = 0.5 min) was taken, placed in a cold test tube and stored
on ice. The sample was taken to the cold room, where a
500jil sample was added to 1 ml of cold methanol, vortex
mixed for 60 s, cooled at - 70°C for 20 min and centrifuged.
The clear supernatant was stored at - 20°C until it was
processed by HPLC. All further time samples were processed
in exactly the same manner.
The protocol used for the drug uptake studies closely
followed the procedure used in the cytotoxicity experiments,
except that the cell suspensions were increased in volume to
40 ml in a 125 ml Erlenmeyer flask, and in concentration to
1.5 x 106 cells ml-', in order to obtain more accurate deter-
minations of intracellular drug concentrations. After pregass-
ing for 60 min with nitrogen, 4 ml ofcold 1 mM RB 6145 was
added to 36 ml of cell suspension. Samples of 20 ml were
withdrawn from the treatment suspension after Smin and
60 min of drug exposure at 37°C. The samples were transfer-
red into cold, preweighed test tubes, placed on ice and cent-
rifuged at 95g for 8 min at 4°C. The medium supernatants
were decanted into cold test tubes and stored at - 20°C. The
insides of the test tubes containing the cell pellets were
swabbed dry and the tubes were weighed again to determine
the mass of the cell pellet. A modified technique of Dennis et
al. (1985) was used to extract the drug from the cell pellet.
Cells were homogenised in 0.4 ml of cold water, and
sonicated with the microtip of the ultrasonicator for 30s.
After cell lysis had been confirmed, 1.5 ml of cold methanol
was added, the sample was vortex mixed for 60 s and cent-
rifuged at 1400g for 5 min. Medium supernatant samples
were processed by adding cold methanol to precipitate pro-
teins, then they were vortex mixed for 60 s, cooled at - 70C
for 20 min and centrifuged. HPLC was used to determine the
concentration of RB 6145 and its products in the medium
extract, Ce, and in the cell pellet, Cp. Inulin ['4C]carboxylic
acid (which does not enter cells) was used in a similar
protocol to determine the fraction, a, of the cell pellet
volume that represented the extracellular volume for each cell
line (Dennis et al., 1985). The intracellular to extracellular
drug concentration ratio, Ci/Ce, was calculated by correcting
the Cp/C, ratio for a.
Analysis of RB 6145 and its derivatives was performed by
reverse phase HPLC, using a Waters model 712 WISP
autoinjector, a model 510 pump and a model 996 photodiode
array detector (Waters Scientific, Mississanga, Ontario,
Canada). Separation of RB 6145 from its products was
achieved using a Waters Resolve 51Am C18 column (3.8
x 300 mm) and a Guard-Pak precolumn (Waters Scientific).
An isocratic mobile phase of 5% acetonitrile in 10 mM potas-
sium dihydrogen phosphate (pH 3.9) was run at 1.0 ml min'-
for 15 min. RB 6145 and its derivatives were detected at
325 nm and chromatograms were processed using the
Millenium Chromatography Manager (Waters Scientific).
The RB 6145, RSU 1069 and RSU 1137 peaks were
identified using standard drug solutions. The oxazolidinone
product was formed by allowing bicarbonate to react with
RB 6145, and then analysed by HPLC to confirm its reten-
tion time and absorption spectrum (Binger and Workman,
1991).
Intracellular pHdetermination
SiHa and HT 29 cells used in the intracellular pH studies
were grown in monolayers, trypsinised, spun down and
resuspended in suspension medium, buffered with Bis-Tris at
A ApH 7.4. The cell concentration was 1 x 106 cells ml-'. We
used the fluorochrome carboxy-seminaphthorhodafluor-1 (C-
SNARF-1) as the pH probe for our flow cytometry
measurements (Bassnett et al., 1990; van Erp et al., 1991;
Seksek et al., 1991). Its absorption spectrum is pH depen-
dent, such that, once calibrated, the ratio of the absorbances
at 575 and 640 nm gives an indication of the pHi as individ-
ual cells are analysed in the flow cytometer. C-SNARF-1 was
added such that the final concentration was 7 LM, and the
suspension was incubated at 37°C for 30 min and then
separated into sample groups. For each experiment there was
a calibration group, two groups that received no drug (one at
pH 6.4, the other at 7.4) and two groups with drug (pH 6.4
and 7.4). The samples were centrifuged at 95g for 10 min at
4°C, the supernatants were poured off and the cells
resuspended at 1 x 106 cells ml1'. The calibration samples
were resuspended in a saline solution containing 115 mM
potassium chloride, 1 mM magnesium chloride and 20 mM
Bis-Tris at a range of pH values (6.0-7.8). The groups with
and without RB 6145 were resuspended in suspension
medium, 10% FBS and 20 mM Bis-Tris at pH 6.4 and 7.4 in
a 50 ml Erlenmeyer flask. The potassium ionophore nigericin
(Orion Research, Boston, MA, USA) was added to the calib-
ration group to equilibrate intra- and extracellular pH and
the samples were incubated at 37°C for 5 min. The calibra-
tion curve samples were kept on ice until they could be
analysed, all other flasks were placed in a rotary shaker bath
at 37°C in a 37°C warm room, and all flasks were gassed with
humidified nitrogen (141 min-'). At this time, t = 0 samples
were taken, by placing a 1 ml aliquot into a small plastic test
tube. The extracellular pH, of the sample was measured
(Orion model 420A; Orion Research) and the sample was
taken to the flow cytometer for processing. A minimum
amount of time elapsed between the external pH measure-
ment and the flow cytometer analysis, especially for the
calibration measurements. After 60 min, RB 6145 in suspen-
sion medium, pH 6.9, was added to the flasks that were to
receive drug such that the final concentration would be
100tLM. The first sample was taken from these vessels 5 min
later, corresponding to the t = 5 min samples in the drug
uptake studies. All samples were analysed using the Coulter
Elite Flow Cytometer (Coulter, Hialeah, FL, USA) which
determined the fluorescence intensity at 640 nm and at
575 nm. The ratio of these two intensities was plotted vs the
measured extracellular pH and the resulting calibration res-
ponse was fitted with a second-order function. This function
was used to determine the intracellular pH from the intensity
ratios (575/640 nm) of the other samples.
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Results
Cytotoxicity
Figure 2 shows the cytotoxic effect of RB 6145 in SiHa cells
(1 h, 37°C) at pH 6.6 and 7.4, under aerobic and hypoxic
conditions. The effect of hypoxia on this cytotoxicity is evi-
dent from the very different (5 x ) drug concentration scales
in Figures 2a and b. It is clear from Figure 2 that low pH
also potentiates the effect of this drug, under both aerobic
and hypoxic conditions. Figure 3 shows the effect of a range
of pH values (6.0-7.4) on the cytotoxic effect of 80tLM RB
6145 in hypoxic SiHa cells, again for a 1 h treatment at 37C.
The potentiation is seen to increase sharply with decreasing
pH. The effect of acid pH alone, without drug, is seen to be
minimal in this figure.
In contrast, HT-29 cells showed no significantly enhanced
effect of RB 6145 by acidic treatment, at least under hypoxic
conditions as shown in Figure 4. Table I summarises these
effects for SiHa and HT-29 cells, as well as for four addi-
tional human tumour cell lines. The enhancement ratios (ER)
are expressed as the ratio of the drug concentrations which
produce two logs of cell kill (SF = 0.01) under the respective
conditions being compared. ERHyp is thus the ratio of the
drug concentrations for aerobic and hypoxic conditions, and
0.0001
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Figure 2 Effect of low pH on the cytotoxicity of RB 6145 in
SiHa cells under (a) hypoxic and (b) aerobic conditions.
Treatments were for I h at 37'C in MEM (+ 10% FCS) buffered
with 20mm Bis-Tris. Data from four experiments.
ERpH is the ratio of the concentrations for pH 7.4 and 6.4
respectively. The effect of low pH and hypoxia on RB 6145
cytotoxicity is clearly cell-line dependent.
In an attempt to determine the basis of this, studies of
drug uptake using HPLC techniques and of intracellular pH
regulation (flow cytometry) were undertaken for SiHa and
HT-29 cells, which show contrasting effects of acidic pH.
HPLC Studies
It has been shown, from in vitro and in vivo studies, that at
37°C and physiological pH, RB 6145 is rapidly altered, yiel-
ding the products RSU 1069 (the aziridine analogue), RSUEffect of pH and hypoxia on RB 6145 cytotoxicity o_ LD Skarsgard etal
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1137 (the hydroxy-ethyl amino analogue) and an oxazolid-
inone derivative, as well as very low levels of other
metabolites (Jenkins et al., 1990; Binger and Workman,
1991). This complicates the use of chromatographic techni-
ques for the study of drug uptake in cultured cells. However,
since the absorption spectra of RB 6145 and each of the
above products are the same, it suggests that an indication of
the total drug present in any sample might be obtained by
summing the absorbances from RB 6145 and the various
derivatives. Figure 5 shows the chromatograms obtained
when 1 ml of cold 1 mM RB 6145 at pH 6.9 was added to
9 ml of MEM S14 containing 10% FBS and 20 mM Bis-Tris
at pH 7.4, 37°C, and then held under hypoxia for a time t, at
37°C followed by methanol extraction and HPLC analysis
(see Methods). Figure 5a and b shows the chromatograms
for t = 0.5 min and t = 3.5 min respectively. Even at
t = 0.5 min more than half of the RB 6145 has been con-
verted to RSU 1069 and the oxazolidinone derivative when
the drug is dissolved in medium. It should be noted, how-
ever, that before t = 0, the sample has been exposed to
medium (or to a 2:1 mixture of methanol/medium) for ap-
proximately 30min at a temperature of 4°C, or lower (see
Methods). When the RB 6145 is dissolved instead in pure
water and processed in the same fashion the t = 0
chromatograph shows more than 97% of the total product as
RB 6145, the remainder being RSU 1069 (data not shown).
At t = 3.5 min in medium (Figure Sb) nearly all of the RB
6145 has been converted to RSU 1069 and oxazolidinone.
Figure 5c shows how the absorbance due to RB 6145 and its
derivatives varies with time in medium at 37°C. It can be seen
that the summed absorbance from these three products re-
mains relatively constant over the time period of this study.
This suggested that determinations of the cellular uptake of
drug might reasonably be estimated by summing the absor-
bances due to RB 6145 and its various derivatives. Important
qualifications in these uptake measurements are: (i) the
HPLC method only detects free, unbound drug within the
cell; any bound drug (e.g. to DNA) will be precipitated out
0.1
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Figure 3 pH dependence of RB 6145 toxicity in hypoxic SiHa
cells. Treatments were for 1 h at 37°C as in Figure 2, RB 6145
concentration was 80 tLM. Data from three experiments. 0, sam-
ples without drug; *, samples with drug.
RB 6145 Toxicity
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0
0 100 200 300
[RB61451 (pM)
Figure 4 Absence of pH effect on the cytotoxicity of RB 6145 in
HT 29 cells under hypoxia. Treatments were for I h at 37°C in
McCoy's Sa ( + 10% FCS) with 20 mM Bis-Tris buffer. Data
from two experiments. 0, Nitrogen, pH 7.4; 0, nitrogen, pH
6.6.
Table I Cytotoxicity of RB 6145 in various human tumour cell lines and the effect of pH
and hypoxia
Concentration for 1%
Treatment No. of survival (gLm)
Cell line condition experiments pH6.6 pH 7.4 ERPHa ERHypb
SiHa Hypoxic 4 95 152 1.61 10.7
SiHa Oxic 2 1OOOC 1620 1.62
UI Hypoxic 3 11C 144 1.43 15.1 Oxic 3 1600c 2170 1.36
HT29 Hypoxic 4 131 142 1.09
A549 Hypoxic 5 254 290 1.14
HT 144 Hypoxic 2 145c 150 1.03
U373 Hypoxic 2 85c 97 1.14
SiHad Hypoxic 3 106c.d 149d 1.4 d
(RSU
1069)
'Calculated as the concentration ratio [Drug] pH74/[Drug] pH6.6 at S=0.01. bCalculated as the
concentration ratio [Drug]OXic/[Drug]hypo,c at S = 0.01, for pH 7.4. cTreatment pH was 6.4.
dTreatment was with RSU 1069, the presumed active derivative of RB 6145.
. . . . . . .
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in the extraction procedure; (ii) any proportion of the drug
which is broken down within the cell to products with
different light absorption characteristics may not be detected.
The HPLC chromatograms for extracellular (supernatant)
and intracellular (pellet) RB 6145 and its derivatives in SiHa
cells incubated at 37°C under hypoxic conditions for 5 min,
are shown in Figure 6a, for pHe 6.4 (solid profiles) and 7.4
(open profiles). It can be seen that after 5 min incubation in
100IM RB 6145 at 370C, pH 6.4, only' 7% of the extracel-
lular drug is still present as RB 6145 (Figure 6a). At pH 7.4
no RB 6145 could be observed after 5 min incubation, con-
sistent with reports that it is less stable at higher pH (Jenkins
et al., 1990; Binger and Workman, 1991). Figure 6b shows
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Decay of RB 6145 in SMEM with 20 mM Bis-Tris
under hypoxia, at 37°C, pH 7.4
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Figure 5 HPLC study of the time course of RB 6145 conversion
under hypoxic incubation in MEM (+ 10% FCS) buffered with
20mM Bis-Tris at 37°C. No cells were present. (a) HPLC
chromatograms after 0.5 min and (b) 3.5 min incubation. (c)
Absorbance vs incubation time for RB 6145, RSU 1069 and
oxazolidinone, as well as the summed absorbance for these three
products (which approximates the total drug). This does not
change significantly over this time period. Three experiments gave
similar results. Samples were extracted with cold methanol.
0 2 4 6 8 10 12 14
Retention time (min)
b
S
Retention time (min)
Figure 6 HPLC chromatograms of RB 6145 and its derivatives
after (a) 5 min and (b) 60 min incubation in hypoxic SiHa cell
suspensions. Open and solid profiles are for incubation pHs of
7.4 and 6.4 respectively. S and P denote supernatant (extracel-
lular) and pellet (intracellular) profiles respectively. Positions of
major products are indicated. Incubation conditions as for Figure
2. Samples were extracted with cold methanol.
Table II Extracellular and intracellular distribution of RB 6145 and its derivatives in SiHa cells
Unidentified
product RSU 1137 RSU 1069 Oxazolidinone RB6145
HPLC (6.3 min)a (7.2min) (8.6 min) (10.6min) (12.0 min)
chromatogram pH % % % % %
Supernatant 5 min 6.4 - - 90.9 2.2 6.9
Pellet 5 min 6.4 4.4 - 82.4 4.8 8.4
Supernatant 60 min 6.4 - 2.6 92.1 5.3 -
Pellet 60 min 6.4 6.0 - 87.4 6.6 -
Supernatant 5 min 7.4 - - 96.3 3.7 -
Pellet 5 min 7.4 3.4 - 92.9 3.7 -
Supernatant 60 min 7.4 - 1.3 93.8 4.9 -
Pellet 60 min 7.4 6.4 - 90.0 3.6 -
aRetention time.
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Table III Uptake of RB 6145 in SiHa and HT 29 cells under
hypoxic conditions
t = 5 min t = 60 min
Ci Ce Ci Cea
(AM) (ILM) CilCeb (AM) (LM) Ci/Ceb
SiHa cells
pH7.4 53±6 101 3 0.53 52±6 102±3 0.51
pH6.4 50±7 97±3 0.52 69±7 97±3 0.71
Relative uptake 0.98 1.39
at low pHc
HT 29 cells
pH7.4 103 12 117 3 0.88 109 12 121 3 0.90
pH6.4 80 12 120 3 0.67 75 12 112 3 0.67
Relative uptake 0.76 0.74
at low pHc
'The nominal treatment concentration was: SiHa cells, 100JAM
RB 6145; HT 29 cells, 111 M RB 6145. bC1/C, ratio of intracellular
to extracellular drug concentrations, corrected for the fraction of
extracellular space in the cell pellet, a, according to the relation
CJ/Ce= [(Cp/Ce) -ar]/(1-ax) where Cp is the pellet concentration
averaged over the intracelluar and extracellular volume (Dennis et
al., 1985). cCalculated as (Ci/C)pH6.4/(Ci/Ce)pH74.
0 ~--O can be seen that the intracellular free drug concentration, Ci,
is lower than CQ in all cases, particularly in SiHa cells. This
could presumably indicate (i) reduced entry of drug into the
cell or (ii) enhanced breakdown of the drug within the cell to
.-- ,--- products with reduced light absorption. In order to check the
0 30 60 90 120 150 180 second possibility, a similar uptake experiment with SiHa
Time (min) cells was carried out at 4°C, where metabolism of the drug
should be substantially reduced. The measured C, at pH 6.4
e 7 Intracellular and extracellular pH in (a) SiHa and (b) in this case was unchanged from the values in Table III for
29 cells incubated at 37°C under hypoxic conditions, in the 37°C, although at pH 7.4 the value ofC, at 4°C was increased
nce and absence of 1I00 JM RB 6145. The respective growth nearly 2-fold, to approximate the extracellular concentration
a (MEM and McCoy's 5a) were buffered with 20 mM Bis- (data not shown).
as in Figures 2 and 4. It is also evident from Table III that in SiHa cells at pH
6.4, the value of Ci and Ci/C, increased significantly over the
60 min incubation, from 0.51 to 0.71, an increase of approx-
imately 39%. This was the only C,/Ce value which increased
)rresponding HPLC profiles following 60 min incuba- significantly during the treatment, in either SiHa or HT 29
4o RB 6145 is evident in any of the 60 min profiles; the cells.
oxazolidinone derivative accounts for approximately 5% of
the total and RSU 1069 for most of the remainder. In the
60 min profiles there is evidence of another minor product
with a retention time of 7.2 min. It is detectable only in the
supernatant samples, accounting for 2.6% and 1.2% of the
total drug at pH 6.4 and 7.4 respectively. Separate studies
have identified this as the hydrolysis product RSU 1137 (see
Figure 1). There is another minor product with a retention
time of 6.3 min which is found only in the pellet samples,
suggesting it may be associated with some cellular metabolic
process. It is present at both pHs and appears to increase
with incubation time from 3-4% at 5 min to -6% at
60 min. This product has not been identified, though it has
the same absorption spectrum as RB 6145 and the other
products. It could be the dealkylation product, RSU 1111
(Binger and Workman, 1991). Table II shows the percentage
distribution of RB 6145 and its metabolites (unbound drug)
in the extracellular (supernatant) and intracellular (pellet)
material from a typical experiment with SiHa cells. It is
described further in the discussion.
HPLC studies with HT 29 cells (profiles not shown) gave
results which were similar to those discussed above for SiHa
cells, with respect to the type and amounts of products
observed.
Table III gives a summary of the values of Ci and C,, the
intracellular and extracellular determinations of free drug
concentration for both cell lines, using these summed absor-
bances for RB 6145, RSU 1069, the oxazolidinone derivative,
RSU 1137 and the unknown product, for total drug measure-
ment. The nominal treatment concentration of RB 6145 was
100 JM in the SiHa study and 111 gAM in the HT 29 study. It
IntracellularpH measurement
In order to determine how well these cells succeeded in
maintaining a neutral intracellular pH (pHi) despite an acidic
extracellular environment, flow cytometry techniques were
used to estimate intracellular pH. Figure 7 shows the results
of these studies in both SiHa and HT-29 cells. It can be seen
that under conditions of neutral extracellular pH, both cell
lines exhibit neutral intracellular pH. For acidic extracellular
conditions, both cell lines were able to maintain a near-
neutral but reduced pHi initially, though in SiHa cells the
pHi dropped to within 0.2 units of the extracellular level,
approximately, within 2 h.
Discussion
The increased cytotoxicity of RB 6145 under hypoxic condi-
tions is clearly evident for SiHa cells in Figure 2. If one
expresses this potentiation by hypoxia as an enhancement
ratio (the ratio of the drug concentrations which give a
surviving fraction of 0.01 under aerobic and hypoxic condi-
tions) the ERHyp for SiHa is 11 at pH 7.4, as shown in Table
I. For Ul cells, ERHyp is approximately 15. These values are
smaller than the hypoxic ERs of 30-40 reported for RSU
1069 in rodent and human cells in vitro (Whitmore and
Gulyas, 1986; Roizin-Towle et al., 1990), but similar to the
value of approximately 15 which can be estimated from the
data of Jenkins et al. (1990) for RB 6145 in V79 cells (3 h
exposures at neutral pH were used in that study). Siemann
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(1994) reported values of ERHyp of 9 and 80 for A549 and
KHT/iv cells respectively, exposed in vitro to RB 6145 at
neutral pH for 4 h. It thus seems likely that values of ERHyp
are cell-line dependent. They may also be affected by
differences in treatment conditions. For example in all of the
studies referred to above (except our own) bicarbonate was
present in the treatment medium, and it has been shown that
bicarbonate greatly increases the conversion of RB 6145 to
oxazolidinone (Jenkins et al., 1990; Binger and Workman,
1991).
Acidic pH also enhanced the cytotoxicity of RB 6145 in
SiHa cells (Figure 2 and 3), giving an enhancement ratio of
approximately 1.6 at pH 6.6, under both aerobic and hypoxic
conditions. Low pH by itself, without drug, had little effect
on plating efficiency (see Figure 3). Since RB 6145 is known
to be more stable in acidic pH (Jenkins et al., 1990; Binger
and Workman, 1991) one might at first think that low pH is
simply preventing metabolic degradation of the drug. Indeed,
Figure 6a shows that after 5 min at 37°C and pH 7.4 there is
no detectable prodrug (RB6145) remaining in the extracel-
lular medium, it has all been converted to RSU 1069 (96%)
or oxazolidinone (4%, see Table II). At pH 6.4 7% of the
drug is still present as RB 6145, 2% as oxazolidinone and
91% as RSU 1069 (Figure 6a and Table II). The total drug
(summed absorbance) in the extracellular medium is essen-
tially the same at both pHs (101 and 97;LM, see Table III),
and is approximately equal to the initial RB 6145 concentra-
tion (100 iM), indicating that there has been no significant
breakdown (hydrolysis) to a non-light-absorbing product. At
t = 60 min, the proportions of drug products in the extracel-
lular medium are essentially the same at both pH 6.4 and 7.4:
-92-94% RSU 1069 and -5% oxazolidinone (plus traces
of other products) and again, the total drug is essentially the
same in the extracellular medium (Table III). Thus, it is
unlikely that the potentiation of RB 6145 cytotoxicity by low
pH in SiHa cells can be explained as an inhibition of drug
metabolism at low pH. As an additional test of this pos-
sibility, an experiment similar to Figure 2 was carried out
using RSU 1069 instead of RB 6145 in SiHa cells. Again, low
pH potentiated the cytotoxic response (ERpH = 1.41, see
Table I). Furthermore, if stabilisation of the drug by low pH
were a part of the explanation for the enhanced cytotoxicity
in SiHa cells (Figure 2) there should have been a similar
enhancement in HT 29 cells. Figure 4 shows no such
enhancement.
It is perhaps more likely that the increased cytotoxicity of
RB 6145 at low pH is related to differences in cellular uptake
of the drug and its products. As shown in Table III, the
value ofCi/Ce in SiHa cells at t = 60 min was -40% higher
at pH 6.4 than at pH 7.4. This was more than enough to
offset the slightly greater drug degradation within the cells: of
the total free drug in the cell pellet at pH 6.4 and 60 min,
87% was present as (active) RSU 1069, 7% as oxazolidinone
and 6% as the unidentified product; in the extracellular
medium, 92% was present as RSU 1069, 5% as oxazolid-
inone and 2.6% as RSU 1137 (Table II). At pH 7.4, 90% of
the free drug in the pellet at 60 min is RSU 1069, while in the
extracellular medium it is 94% (Table II). (Note that these
percentage distributions of the various drug derivatives in the
cell pellet are only approximately representative of the int-
racellular drug concentration since they have not been cor-
rected for the effect of the extracellular space in the cell
pellet. The values of Ci in Table II, however, have been
corrected for this.) The proportion of RB 6145 converted to
oxazolidinone is much lower in our studies (4-7% at 60 min)
than has been reported by Binger and Workman (1991) for in
vivo studies (-equal proportions of oxazolidinone and RSU
1069 at 45 min.), presumably due to the presence (in mouse
blood) of hydrogen carbonate which assists this conversion.
The relevance of this is unclear since the cytotoxic effect of
oxazolidinone has not been examined (Binger and Workman,
1991).
HT 29 cells, which had shown no potentiation of RB 6145
effects by low pH, showed no selective drug uptake at low
pH, in fact, uptake was somewhat lower at pH 6.4 (Table
III). These results are thus consistent with the hypothesis that
enhanced cytotoxicity of RB 6145 in acidic extracellular
environments is at least in part associated with pH-dependent
changes in drug uptake and that this may be a cell-line
dependent phenomenon. In this connection, it should be
noted that in studies of the derivative RSU 1069, Walling et
al., found no effect of pH on the uptake of RSU 1069 in V79
cells, and radiosensitisation by RSU 1069 was also unaffected
by pH (Walling et al., 1988). They did not describe the effect
of pH on the cytotoxicity of RSU 1069.
Our measurements of intracellular pH showed that SiHa
cells were somewhat less successful than HT 29 cells at
maintaining a near-neutral pHi in the face of an acidic ext-
racellular environment, as shown in Figure 7. In SiHa cells,
pHi dropped to within -0.2 pH units ofpH, in 2 h, whether
RB 6145 was present or not. Figure 3 shows that low pH by
itself is not significantly toxic to SiHa cells for the time
intervals used in these studies. However, there could still be
potentiating interaction between pH and drug-induced cel-
lular lesions; if, for example, acidic pH were to result in a
drop in intracellular glutathione (GSH) one could expect a
reduction in binding of alkylating species and an increase in
damage from such active drug metabolites. At this point it is
unclear what the precise consequences of this apparently
diminished buffering capacity might be in SiHa cells at low
pH.
One can envisage a scenario which would fit with all of our
observations regarding cytotoxicity, uptake and intracellular
pH for both cell lines: if we postulate that low pHi, of itself,
potentiates damage from cytotoxic lesions to a modest, and
for a given pH, similar extent in both SiHa and HT 29 cells,
the differences in pH effects between the two cell lines could
be explained on the basis of their different uptake and pH
control characteristics, as seen in our experiments: i.e in HT
29 cells the inherent pH-enhanced damage would be offset by
reduced uptake in these cells (relative uptake at 60 min is
0.74 in HT 29, see Table III), whereas in SiHa cells it would
be augmented by increased uptake (relative uptake at 60 min
is 1.4 in SiHa, Table III) and perhaps also by the fact that
pHi is somewhat lower in SiHa than in HT 29 cells, during
the period of treatment.
Whatever the explanation, the influence of pH on the
cytotoxicity of RB 6145 and its derivatives, particularly RSU
1069, and the variability of this effect among different human
tumour cell lines, may be important to the clinical applica-
tion of this new drug since, like hypoxia, low pH is a
common and variable feature of the microenvironment of
solid tumours.
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